SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

$HSIC
Medical Specialities
Health Care
Get the next $HSIC alert in real time by email
SC 13G/A 1 generation-hsic123121a5.htm



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G/A 

 

Under the Securities Exchange Act of 1934

(Amendment No. 5)* 


 

Henry Schein, Inc.
(Name of Issuer)

 

 

Common Stock, par value $0.01 per share
(Title of Class of Securities)

 

 

806407102

(CUSIP Number)

 

 

December 31, 2021
(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

 

CUSIP No. 806407102
 SCHEDULE 13G/A
Page 2 of 11 Pages
         
1
NAME OF REPORTING PERSONS
 
Generation Investment Management LLP
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
England and Wales
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
96,932
6
SHARED VOTING POWER
 
13,378,512
7
SOLE DISPOSITIVE POWER
 
96,932
8
SHARED DISPOSITIVE POWER
 
13,378,512
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
13,475,444
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
9.72%
12
TYPE OF REPORTING PERSON
 
IA

 

 
 

 

CUSIP No. 806407102
 SCHEDULE 13G/A
Page 3 of 11 Pages
         
1
NAME OF REPORTING PERSONS
 
Generation Investment Management US LLP
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
6,604,609
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
6,604,609
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
6,604,609
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
4.76%
12
TYPE OF REPORTING PERSON
 
IA

 

 
 

 

CUSIP No. 806407102
 SCHEDULE 13G/A
Page 4 of 11 Pages
         
1
NAME OF REPORTING PERSONS
 
Generation IM Fund plc
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Ireland
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
4,086,109
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
4,086,109
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
4,086,109
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
2.95%
12
TYPE OF REPORTING PERSON
 
CO

 

 
 

 

CUSIP No. 806407102
 SCHEDULE 13G/A
Page 5 of 11 Pages
         
1
NAME OF REPORTING PERSONS
 
Generation IM Global Equity Fund LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
3,526,609
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
3,526,609
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,526,609
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
2.54%
12
TYPE OF REPORTING PERSON
 
OO

 

 
 

 

CUSIP No. 806407102
 SCHEDULE 13G/A
Page 6 of 11 Pages

 

Item 1.(a) Name of Issuer

Henry Schein, Inc.

(b) Address of Issuer’s Principal Executive Offices

135 Duryea Road

Melville, New York 11747

Item 2.(a) Name of Person Filing

Generation Investment Management LLP;

Generation Investment Management US LLP;

Generation IM Fund plc; and

Generation IM Global Equity Fund LLC.

(b) Address of Principal Business Office, or, if none, Residence

Generation Investment Management LLP: 20 Air Street, 7th floor, London, United Kingdom W1B 5AN.

Generation Investment Management US LLP: 555 Mission Street, Suite 3400, San Francisco, CA 94105.

Generation IM Fund plc: Georges Court, 54-62 Townsend Street, Dublin 2, Ireland.

Generation IM Global Equity Fund LLC: c/o 555 Mission Street, Suite 3400, San Francisco, CA 94105.

(c) Citizenship

Generation Investment Management LLP – England and Wales

Generation Investment Management US LLP - Delaware

Generation IM Fund plc - Ireland

Generation IM Global Equity Fund LLC - Delaware

 (d) Title of Class of Securities

Common Stock, par value $0.01 per share

 (e) CUSIP No.:

806407102

 
 

 

CUSIP No. 806407102
 SCHEDULE 13G/A
Page 7 of 11 Pages

 

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

  (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
 
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
 
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
 
  (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
 
  (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
 
  (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
 
  (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
  (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
  (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
 
  (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
       

 
 

 

CUSIP No. 806407102
 SCHEDULE 13G/A
Page 8 of 11 Pages

 

 

Item 4. Ownership

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a) Amount beneficially owned:

See the response(s) to Item 9 on the attached cover pages.

(b) Percent of class:

See the response(s) to Item 11 on the attached cover pages.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover pages.

(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover pages.

(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover pages.

(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover pages.

Item 5. Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following:

Not applicable

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

 

Not Applicable

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

 

Not Applicable

Item 8. Identification and Classification of Members of the Group

 

Not Applicable

Item 9. Notice of Dissolution of Group

 

Not Applicable

Item 10. Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 



 
 
CUSIP No.  806407102
 SCHEDULE 13G/A
Page 9 of 11 Pages

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2022

  

  GENERATION INVESTMENT MANAGEMENT LLP
       
  By:  /s/ Alexander Marshall
    Name:  Alexander Marshall
    Title:  General Counsel & Chief Compliance Officer

 

  GENERATION INVESTMENT MANAGEMENT US LLP
 

By: Generation Investment Management Services LLC

Its: Partner

       
  By:  /s/ Ghessycka Lucien Bennett
    Name:  Ghessycka Lucien Bennett
    Title:  US Chief Compliance Officer

 

  GENERATION IM FUND PLC
       
  By:  /s/ Flavia Lugangira
    Name:  Flavia Lugangira
    Title:  Director

 

  GENERATION IM GLOBAL EQUITY FUND LLC
       
  By:  /s/ Ghessycka Lucien Bennett
    Name:  Ghessycka Lucien Bennett
    Title:  US Chief Compliance Officer

 

 

 

 



 
 
CUSIP No.  806407102
 SCHEDULE 13G/A
Page 10 of 11 Pages

 

 

INDEX TO EXHIBITS

 

Exhibit No.  Exhibit

99.1               Joint Filing Agreement

 



 
 
CUSIP No.  806407102
 SCHEDULE 13G/A
Page 11 of 11 Pages

 

 

Exhibit 99.1

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to such statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entity or person, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

 

Dated: February 14, 2022

  GENERATION INVESTMENT MANAGEMENT LLP
       
  By:  /s/ Alexander Marshall
    Name:  Alexander Marshall
    Title:  General Counsel & Chief Compliance Officer

 

  GENERATION INVESTMENT MANAGEMENT US LLP
 

By: Generation Investment Management Services LLC

Its: Partner

       
  By:  /s/ Ghessycka Lucien Bennett
    Name:  Ghessycka Lucien Bennett
    Title:  US Chief Compliance Officer

 

  GENERATION IM FUND PLC
       
  By:  /s/ Flavia Lugangira
    Name:  Flavia Lugangira
    Title:  Director

 

  GENERATION IM GLOBAL EQUITY FUND LLC
       
  By:  /s/ Ghessycka Lucien Bennett
    Name:  Ghessycka Lucien Bennett
    Title:  US Chief Compliance Officer
Get the next $HSIC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HSIC

DatePrice TargetRatingAnalyst
2/14/2025$80.00Equal Weight
Wells Fargo
1/6/2025$69.00 → $84.00Underperform → Buy
BofA Securities
12/4/2024$75.00Neutral
Mizuho
7/22/2024$81.00 → $92.00Neutral → Outperform
Robert W. Baird
2/26/2024$78.00Market Perform
Leerink Partners
12/12/2023$71.00 → $82.00Neutral → Overweight
JP Morgan
11/10/2023$70.00Hold → Buy
Stifel
8/8/2022$80.00Sell → Neutral
UBS
More analyst ratings

$HSIC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Henry Schein Will Showcase a Selection of the Company's Comprehensive Solutions for Oral Health Professionals at the 2025 International Dental Show

    Media roundtable sessions: "Conversations with Henry Schein: Exploring the Present and Future of Oral Health" will take place to discuss digitalization in dentistry; Henry Schein will also feature "FDI's Integrated Electronic Health Records Project." The Company will present an expansive portfolio of products and solutions, designed to help oral health professionals enhance practice efficiency and the patient experience, and will offer endodontic hands-on courses with Key Opinion Leaders at the booth. Henry Schein, Inc. (NASDAQ:HSIC) will showcase a selection of its comprehensive business and practice solutions, and provide perspectives on the future of dentistry, during the 2025 Inter

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Donates Health Care Products to Support Special Olympics Healthy Athletes® Screenings at Special Olympics World Winter Games 2025 in Turin, Italy

    With This Donation, The Company Promotes Wellness, Prevention, and Health Education for Athletes With Intellectual Disabilities Around the World Henry Schein, Inc. – the world's largest provider of health care solutions to office-based dental and medical practitioners – is supporting the Special Olympics Healthy Athletes® screenings at the Special Olympics World Winter Games Turin 2025, which take place from March 8 to 15, 2025, in Turin, Italy. The organization is donating a range of oral health and medical products essential to overall health and wellness. During the Healthy Athletes Ribbon Cutting Ceremony, on March 8, 2025, Henry Schein was recognized for these contributions. Healthy A

    $HSIC
    Medical Specialities
    Health Care
  • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    $BAX
    $BMRN
    $EMBC
    $HSIC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

$HSIC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HSIC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HSIC
SEC Filings

See more

$HSIC
Leadership Updates

Live Leadership Updates

See more
  • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    $BAX
    $BMRN
    $EMBC
    $HSIC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities
  • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

    $BAX
    $BMRN
    $EMBC
    $HSIC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities
  • Give Kids A Smile Program Celebrates 23rd Year of Providing Free Oral Health Care Services to Underserved Children

    The American Dental Association Foundation's Initiative, with Exclusive National Sponsors Henry Schein and Colgate-Palmolive, Continues to Expand Its Reach, With Nearly 325,500 Children Expected to Receive Care Throughout 2025 The American Dental Association Foundation (ADA Foundation) is celebrating the 23rd year of its Give Kids A Smile® (GKAS) program, which officially launched on Friday, February 7, at the 2025 national kick-off event at Meharry Medical College School of Dentistry. Since its national launch in 2003, GKAS volunteers have provided free oral health education and services to more than 9.5 million underserved children in the U.S. This press release features multimedia. Vi

    $CL
    $HSIC
    Package Goods/Cosmetics
    Consumer Discretionary
    Medical Specialities
    Health Care

$HSIC
Financials

Live finance-specific insights

See more
  • Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Detailed 2025 Financial Guidance

    Fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19 Fourth-quarter 2024 operating cash flow of $204 million; full-year 2024 operating cash flow of $848 million, up $348 million compared with 2023 2025 non-GAAP diluted EPS expected to be in the range of $4.80 to $4.94 with mid-single digit 2025 Adjusted EBITDA growth Announces new reportable segments to provide more meaningful information for investors Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter and full year ended December 28, 2024. The financial result

    $HSIC
    Medical Specialities
    Health Care
  • Henry Schein Announces Strategic Investment by KKR, Board Changes and Provides Preliminary Unaudited Financial Results and 2025 Financial Guidance

    KKR to become 12% common shareholder in Henry Schein Henry Schein and KKR to collaborate on range of value creation opportunities Two KKR representatives with deep sector experience to join the Henry Schein Board as independent directors Separately, Robert J. Hombach, who brings extensive financial and strategic experience in health care, has joined the Henry Schein Board as an independent director Announces preliminary unaudited fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19, and preliminary 2025 financial guidance for full-year non-GAAP EPS of low to mid single digit growth In addition, Henry Schein has increased its share repurchase progra

    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance
  • Henry Schein to Webcast Fourth Quarter and Full-Year 2024 Conference Call on Tuesday, February 25, 2025, at 8:00 a.m. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter and full-year 2024 financial results before the stock market opens on Tuesday, February 25, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay

    $HSIC
    Medical Specialities
    Health Care

$HSIC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more